Therapeutic area
First-Line Study for Advanced Lung Cancer with a KRAS G12C Mutation
Therapeutic area
Oncology — Lung Cancer
General profile of the patient sought
Intended for people with stage IIIB–IV non-small cell lung cancer, a confirmed KRAS G12C mutation, and a known PD-L1 result. Participants must have an ECOG performance status of 0–1, meaning they are fully active or have mild limitations with physically strenuous activities. The study is intended for people who have not previously received treatment for this disease, although the protocol allows a limited exception for urgent treatment. Participation also depends on tumor type, the absence of other actionable molecular alterations, and additional medical criteria reviewed by the research team.
Principal investigator
Dr. Carlos Zuloaga
A clinical study evaluating combination treatments as first-line therapy for people with advanced or metastatic non-small cell lung cancer and a KRAS G12C mutation. The treatments being studied include targeted therapy and immunotherapy, with or without chemotherapy, depending on the tumor’s characteristics.